Uncategorized
What’s Going On With Sonder Shares Today: What’s Going On?
Sonder Holdings Inc. (NASDAQ: SOND) are trading higher Monday after the company announced a set of financial and strategic actions aimed at improving its balance sheet and operational efficiency. read more
Chip Shock: 3 Hot Semiconductor ETFs To Watch As Trump’s Tariff Bomb Ticks
Tariffs on foreign semiconductors may remake supply chains and spook markets. Investors focus on ETFs with heavy chipmaker exposure. read more
What’s Going On With Micron Technology Stock Monday?
Micron shares are moving higher on Monday after President Donald Trump and his administration announced that electronics are exempt from the 145% reciprocal tariffs on Chinese goods. read more
A Glimpse Into The Expert Outlook On Helmerich & Payne Through 7 Analysts
Latest Ratings for HP Date Firm Action From To Feb 2022 Morgan Stanley Maintains Underweight Dec 2021 Morgan Stanley Downgrades Equal-Weight Underweight Nov 2021 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for HP View the Latest Analyst Ratings read more
What 9 Analyst Ratings Have To Say About Ingersoll Rand
Latest Ratings for IR Date Firm Action From To Feb 2022 Deutsche Bank Maintains Buy Feb 2022 Credit Suisse Maintains Neutral Feb 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for IR View the Latest Analyst Ratings read more
What 16 Analyst Ratings Have To Say About Westlake
Latest Ratings for WLK Date Firm Action From To Feb 2022 Citigroup Maintains Buy Feb 2022 Wells Fargo Maintains Overweight Jan 2022 Goldman Sachs Maintains Neutral View More Analyst Ratings for WLK View the Latest Analyst Ratings read more
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies. read more
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Certara reports $106M Q1 revenue, authorizes $100M buyback, and launches a new AI-driven non-animal testing tool to support biopharma innovation. read more
The Analyst Verdict: ITT In The Eyes Of 5 Experts
Latest Ratings for ITT Date Firm Action From To Dec 2021 B of A Securities Upgrades Neutral Buy Aug 2021 Oppenheimer Maintains Outperform Aug 2021 Keybanc Maintains Overweight View More Analyst Ratings for ITT View the Latest Analyst Ratings read more